Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance

Journal of Biological Chemistry

Volumn 288, Issue 8, 2013, Pages 5673-5681

  O'Meara, Jeff A ^a   Lemke, Christopher T ^a   Godbout, Cédrickx ^a   Kukolj, George ^a   Lagacé, Lisette ^a   Moreau, Benoǐt ^a   Thibeault, Diane ^a   White, Peter W ^a   Llinás Brunet, Montse ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRALS; HEPATITIS C; HEPATITIS C VIRUS; INVARIANT REGIONS; MOLECULAR MECHANISM; PROTEASE INHIBITOR;

ENZYME INHIBITION;

VIRUSES;

FALDAPREVIR; MACROCYCLIC ACYLSULFONAMIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE INHIBITOR; SIMEPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CELL LINE; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS C; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS; X-RAYS;

EID: 84874326584     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.439455     Document Type: Article

References (40)

1. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. (1989) Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 244, 359-362
2. Lavanchy, D. (2009) The global burden of hepatitis C. Liver Int. 29, 74-81
3. Ghany, M. G., Strader, D. B., Thomas, D. L., Seeff, L. B., and American Association for the Study of Liver Diseases. (2009) Diagnosis, management, and treatment of hepatitis C. An update. Hepatology 49, 1335-1374
4. Moradpour, D., Penin, F., and Rice, C. M. (2007) Replication of hepatitis C virus. Nat. Rev. Microbiol. 5, 453-463
5. Kim, J. L., Morgenstern, K. A., Lin, C., Fox, T., Dwyer, M. D., Landro, J. A., Chambers, S. P., Markland, W., Lepre, C. A., O'Malley, E. T., Harbeson, S. L., Rice, C. M., Murcko, M. A., Caron, P. R., and Thomson, J. A. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355
6. Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R. E., Calleja, J. L., Forns, X., Erhardt, A., Crönlein, J., Chaves, R. L., Yong, C. L., Nehmiz, G., and Steinmann, G. G. (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355
7. Malcolm, B. A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., Chase, R., Gheyas, F., Hart, A., Hesk, D., Ingravallo, P., Jiang, C., Kong, R., Lu, J., Pichardo, J., Prongay, A., Skelton, A., Tong, X., Venkatraman, S., Xia, E., Girijavallabhan, V., and Njoroge, F. G. (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50, 1013-1020
8. Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., Heiser, A., Kalkeri, G., Kolaczkowski, E., Lin, K., Luong, Y. P., Rao, B. G., Taylor, W. P., Thomson, J. A., Tung, R. D., Wei, Y., Kwong, A. D., and Lin, C. (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50, 899-909
9. Poordad, F., McCone, J., Jr., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., DiNubile, M. J., Sniukiene, V., Brass, C. A., Albrecht, J. K., Bronowicki, J. P., and SPRINT-2 Investigators (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206
10. Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., George, J., Rizzetto, M., Shouval, D., Sola, R., Terg, R. A., Yoshida, E. M., Adda, N., Bengtsson, L., Sankoh, A. J., Kieffer, T. L., George, S., Kauffman, R. S., Zeuzem, S., and ADVANCE Study Team (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416
11. White, P. W., Llinàs-Brunet, M., Amad, M., Bethell, R. C., Bolger, G., Cordingley, M. G., Duan, J., Garneau, M., Lagacé, L., Thibeault, D., and Kukolj, G. (2010) Preclinical characterization of BI 201335, a C-terminal carbosylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 54, 4611-4618
12. Lin, T. I., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., Vrang, L., de Kock, H., Wigerinck, P., Raboisson, P., and Simmen, K. (2009) In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother. 53, 1377-1385
13. Sarrazin, C., and Zeuzem, S. (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138, 447-462
14. Manns, M. P., Bourlière, M., Benhamou, Y., Pol, S., Bonacini, M., Trepo, C., Wright, D., Berg, T., Calleja, J. L., White, P. W., Stern, J. O., Steinmann, G., Yong, C. L., Kukolj, G., Scherer, J., and Boecher, W. O. (2011) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 54, 1114-1122
15. Tanwar, S., Trembling, P. M., and Dusheiko, G. M. (2012) TMC435 for the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs 21, 1193-1209
16. Lagacé, L., White, P. W., Bousquet, C., Dansereau, N., Dô, F., Llinas-Brunet, M., Marquis, M., Massariol, M. J., Maurice, R., Spickler, C., Thibeault, D., Triki, I., Zhao, S., and Kukolj, G. (2012) In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 56, 569-572
17. Lenz, O., Verbinnen, T., Lin, T. I., Vijgen, L., Cummings, M. D., Lindberg, J., Berke, J. M., Dehertogh, P., Fransen, E., Scholliers, A., Vermeiren, K., Ivens, T., Raboisson, P., Edlund, M., Storm, S., Vrang, L., de Kock, H., Fanning, G. C., and Simmen, K. A. (2010) In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54, 1878-1887
18. Mehellou, Y., and De Clercq, E. (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and where do we gö J. Med. Chem. 53, 521-538
19. Welsch, C., and Zeuzem, S. (2012) Will interferon-free regimens prevail? Gastroenterology 142, 1351-1355
20. Pawlotsky, J. M. (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53, 1742-1751
21. Ohtaka, H., and Freire, E. (2005) Adaptive inhibitors of the HIV-1 protease. Prog. Biophys. Mol. Biol. 88, 193-208
22. Muzammil, S., Armstrong, A. A., Kang, L. W., Jakalian, A., Bonneau, P. R., Schmelmer, V., Amzel, L. M., and Freire, E. (2007) Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J. Virol. 81, 5144-5154
23. Nalam, M. N., Ali, A., Altman, M. D., Reddy, G. S., Chellappan, S., Kairys, V., Ozen, A., Cao, H., Gilson, M. K., Tidor, B., Rana, T. M., and Schiffer, C. A. (2010) Evaluating the substrate-envelope hypothesis. Structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 84, 5368-5378
24. Ozer, N., Schiffer, C. A., and Haliloglu, T. (2010) Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. Biophys. J. 99, 1650-1659
25. Lemke, C. T., Goudreau, N., Zhao, S., Hucke, O., Thibeault, D., Llinàs-Brunet, M., and White, P. W. (2011) Combined x-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335. J. Biol. Chem. 286, 11434-11443
26. Yee, N. K., Farina, V., Houpis, I. N., Haddad, N., Frutos, R. P., Gallou, F., Wang, X. J., Wei, X., Simpson, R. D., Feng, X., Fuchs, V., Xu, Y., Tan, J., Zhang, L., Xu, J., Smith-Keenan, L. L., Vitous, J., Ridges, M. D., Spinelli, E. M., Johnson, M., Donsbach, K., Nicola, T., Brenner, M., Winter, E., Kreye, P., and Samstag, W. (2006) Efficient large scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis. J. Org. Chem. 71, 7133-7145
27. Llinàs-Brunet, M., Bordeleau, J., Godbout, C., Leblanc, M., Moreau, B., and O'Meara, J. (June 3, 2011) Hepatitis C Inhibitor Compounds. U. S. Patent WO 2011/063502 A1
28. Thibeault, D., Massariol, M. J., Zhao, S., Welchner, E., Goudreau, N., Gingras, R., Llinàs-Brunet, M., and White, P. W. (2009) Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A. Biochemistry 48, 744-753
29. Massariol, M. J., Zhao, S., Marquis, M., Thibeault, D., and White, P. W. (2010) Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Biochem. Biophys. Res. Commun. 391, 692-697
30. Thibeault, D., Bousquet, C., Gingras, R., Lagacé, L., Maurice, R., White, P. W., and Lamarre, D. (2004) Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 78, 7352-7359
31. Irvine, G. B., Ennis, M., and Williams, C. H. (1990) Visual detection of peptidase activity using fluorogenic substrates in a microtiter plate assay. Anal. Biochem. 185, 304-307
32. Pflugrath, J. W. (1999) The finer things in x-ray diffraction data collection. Acta Crystallogr. D Biol. Crystallogr. 55, 1718-1725
33. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., Mc-Coy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221
34. Di Marco, S., Rizzi, M., Volpari, C., Walsh, M. A., Narjes, F., Colarusso, S., De Francesco, R., Matassa, V. G., and Sollazzo, M. (2000) Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two proteaseinhibitor complexes. J. Biol. Chem. 275, 7152-7157
35. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132
36. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21
37. Tsantrizos, Y. S., Bolger, G., Bonneau, P., Cameron, D. R., Goudreau, N., Kukolj, G., LaPlante, S. R., Llinàs-Brunet, M., Nar, H., and Lamarre, D. (2003) Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Ed. Engl. 42, 1356-1360
38. Cummings, M. D., Lindberg, J., Lin, T. I., de Kock, H., Lenz, O., Lilja, E., Felländer, S., Baraznenok, V., Nyström, S., Nilsson, M., Vrang, L., Edlund, M., Rosenquist, A., Samuelsson, B., Raboisson, P., and Simmen, K. (2010) Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew. Chem. Int. Ed. Engl. 49, 1652-1655
39. Berger, K., Bethell, R., Cartier, M., Lagace, L., Triki, I., Marquis, M., Cote-Martin, A., Massariol, M. J., Boecher, W. O., Davis, G. L., Scherer, J., Steinmann, G., Stern, J. O., and Kukolj, G. (2012) Analysis of the emergence and persistence of HCV NS3 variants during the BI 201335 phase 2 SILEN-C trials (C1, C2, and C3). Rev. Antiviral Therapy & Infectious Dis. 6, 29
40. Romano, K. P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L. M., Silver, C., Cao, H., Newton, A., Petropoulos, C. J., Huang, W., and Schiffer, C. A. (2012) The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8, e1002832